Healing Europe's Jobs Disease - Applied Clinical Trials

ADVERTISEMENT

See our 2012 Buyers Guide Digital Edition.
Find Pharma Search Engine
Healing Europe's Jobs Disease

Source: Applied Clinical Trials



Peter O'Donnell
The constant refrain of European politicians is the urgent need to create jobs—no surprise in a continent with high and rising unemployment. Across the European Union, 25 million people were jobless this autumn, and in Spain and Greece there is now a quarter of the working population without jobs.

Inevitably, the search is on for sectors that offer the best hopes of boosting employment—and healthcare is increasingly seen as one of the most promising sectors to examine. The pharmaceutical industry in Europe already sets a fine example. According to figures from its principal European federation, EFPIA, its members employed 660,000 people directly in 2011.

Germany is the largest employer, generating more than 100,000 direct pharma sector jobs, and is closely followed by France, with 97,000. The United Kingdom and Italy come next, each with more than 66,000. And Spain, Switzerland, Poland, and Belgium each provide more than 30,000 jobs. Ireland, Hungary, Romania, and Denmark each generate more than 20,000 as well.

Not only does the sector create direct jobs, but it generated three to four times more employment indirectly—upstream and downstream, says EFPIA. This is attributed largely to its research function, and, EFPIA points out, many of these indirect jobs are of high value, in areas such as clinical science or in academia. The presence of a highly-skilled workforce was one of the key factors in the industry investing €27.5 billion in R&D in Europe last year, it says.

The industry story gets better and better, claims EFPIA. Direct employment has risen to its current level from just over 500,000 in 1990—something like a 35% increase in a decade. And at the same time, the number of direct employees in research has risen too—from 76,000 to 116,000, an even steeper rate of increase.


ADVERTISEMENT

blog comments powered by Disqus

ADVERTISEMENT

UPCOMING CONFERENCES

Access Programs for Investigational and Pre-Launch Drugs
Philadelphia, PA | July 17-18, 2013
Request Brochure

Strategic Pipeline Planning & Portfolio Valuation
Philadelphia, PA | August 13-14, 2013
Request Brochure

MES 2013 - Forum on Manufacturing Execution Systems
Philadelphia, PA | August 14-15, 2013
Request Brochure

Mobile Innovation for the Life Sciences Industry
Philadelphia, PA | August 20-21, 2013
Request Brochure

See All Conferences >>

FindPharma
Survey
As it creates a plan to implement the US biosimilar pathway, should FDA:
Borrow heavily from EMA's pathway program?
Borrow lightly from EMA's pathway program?
Create entirely its own pathway program?
Borrow heavily from EMA's pathway program?
94%
Borrow lightly from EMA's pathway program?
0%
Create entirely its own pathway program?
6%
View Results
Untitled Document
Source: Applied Clinical Trials,
Click here